Abstract | BACKGROUND:
Chemotherapy-induced nausea and vomiting (CINV) is a troublesome side-effect of chemotherapy in pediatric patients undergoing osteosarcoma treatment. In this context, the role of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists needs to be explored. OBJECTIVES: MATERIAL AND METHODS: In this double-blind, randomized study, pediatric patients were assessed in terms of acute nausea and vomiting following HEC for osteosarcoma. These children were assigned to group 1 ( palonosetron) and group 2 ( granisetron) without any other antiemetic prophylaxis. The primary outcome variable was the children's segment with a complete response (CR) during the acute phase of the 1st on-study chemotherapy cycle. The risk factors associated with the emesis were analyzed. The patients were followed up for the first 24 h after chemotherapy. RESULTS: A total number of 200 children were evaluated in terms of the response, and other factors that might alter the response were assessed in the 2 groups. These 200 children underwent 604 blocks of chemotherapy. Complete responses were documented in 83% and 72% of children receiving palonosetron and granisetron, respectively, during the acute phase. Only dexamethasone, used as a rescue medication, was found to be a significant risk factor that predisposed to the response (p < 0.05). CONCLUSIONS:
|
Authors | Zheng Li, Chun Li, Ping Li, Yugang Li, Jin Lai, Sanjay Rastogi |
Journal | Advances in clinical and experimental medicine : official organ Wroclaw Medical University
(Adv Clin Exp Med)
Vol. 31
Issue 3
Pg. 223-230
(Mar 2022)
ISSN: 1899-5276 [Print] Poland |
PMID | 35302300
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Isoquinolines
- Quinuclidines
- Palonosetron
- Dexamethasone
|
Topics |
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Child
- Dexamethasone
(therapeutic use)
- Humans
- Isoquinolines
(therapeutic use)
- Nausea
(chemically induced, drug therapy, prevention & control)
- Osteosarcoma
(chemically induced, drug therapy)
- Palonosetron
(therapeutic use)
- Quinuclidines
(therapeutic use)
- Vomiting
(chemically induced, drug therapy, prevention & control)
|